Hard to Treat Diseases Inc. (HTDS) Stock
Hard to Treat Diseases Inc. (HTDS), founded in 2009 and headquartered in Shenzhen, China, is a pharmaceutical firm engaged in the development, manufacturing, and global export of biopharmaceutical products and vaccines.
Valuation
Financials & Margins
Valuation & Return Ratios
Ownership
Peer Comparison
About Hard to Treat Diseases Inc.
Hard to Treat Diseases Inc. (HTDS), founded in 2009 and headquartered in Shenzhen, China, is a pharmaceutical firm engaged in the development, manufacturing, and global export of biopharmaceutical products and vaccines. The company's extensive portfolio includes a range of biological agents such as reteplase (rPA), mycobacterium vaccae, acutobin urinary kallidinogenase, ulinastatin, and cerebroprotein hydrolysate for injection. HTDS also provides various chemical pharmaceuticals, including cobratide injection, entecavir capsules, HES, dasatinib tablets, thymosin a1 for injection, imipenem and cilastatin sodium for injection, and meropenem for injection. Additionally, it supplies critical vaccines for rabies, ACYW135 meningococcal disease, influenza, Hepatitis A, and varicella. HTDS distributes its offerings through a sales network primarily focused on markets in South Asia, Southeast Asia, Central and South America, and the Middle East.
Hard to Treat Diseases Inc. (HTDS) stock trades at $0.00 with a market capitalization of $109647. Over the past 52 weeks the stock has ranged between $0.00 and $0.00, and currently trades —% below its 52-week high.
On profitability, Hard to Treat Diseases Inc. generates an operating margin of 17.27%, a net profit margin of 15.82%.
Official website: www.htdsmedical.com